División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Ranchería Sur, Cuarta Sección, C.P. 86650, Comalcalco, Tabasco, Mexico.
Mol Biol Rep. 2013 Feb;40(2):2053-8. doi: 10.1007/s11033-012-2264-x. Epub 2012 Nov 27.
The gene coding for catecol-o-methyltransferase (COMT), participant in the metabolism of catecholamines, has long been implicated as a candidate gene for schizophrenia. We determined the relation of the COMT Val108/158Met polymorphism with schizophrenia or its symptomatology (negative, disorganized and psychotic dimension). We conducted a case-control study comprising 186 patients with schizophrenia and 247 controls. The diagnosis of schizophrenia was established using the DSM-IV criteria for this illness. The clinical symptomatology was assessed through the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms. No significant differences were found in the distribution of alleles (χ2 = 0.01, df = 1, p = 0.90) or genotypes (χ2 = 1.66, df = 2, p = 0.43) between schizophrenic patients and the control group. Multivariate analysis showed that the COMT Val108/158Met polymorphism has no influence in the clinical symptomatology of schizophrenia. Our results showed no association between COMT Val108/158Met and schizophrenia or evidence for an association between COMT and the clinical symptomatology of this illness. This suggests that the COMT gene may not contribute to the risk for schizophrenia among the Mexican population.
儿茶酚-O-甲基转移酶（COMT）基因参与儿茶酚胺的代谢，长期以来一直被认为是精神分裂症的候选基因。我们确定了 COMT Val108/158Met 多态性与精神分裂症或其症状（阴性、紊乱和精神病维度）的关系。我们进行了一项病例对照研究，包括 186 名精神分裂症患者和 247 名对照。精神分裂症的诊断采用 DSM-IV 标准。临床症状通过阴性症状评定量表和阳性症状评定量表进行评估。在精神分裂症患者和对照组之间，等位基因（χ2=0.01，df=1，p=0.90）或基因型（χ2=1.66，df=2，p=0.43）的分布无显著差异。多变量分析表明，COMT Val108/158Met 多态性对精神分裂症的临床症状没有影响。我们的结果表明，COMT Val108/158Met 与精神分裂症之间没有关联，也没有证据表明 COMT 与这种疾病的临床症状之间存在关联。这表明 COMT 基因可能不会增加墨西哥人群患精神分裂症的风险。
